User: Guest

TRADITIONAL WOUND MANAGEMENT PRODUCTS

Global Market Trajectory & Analytics

MCP-8105

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

13851

Interactions with Platform & by Email *

INTERACTIONS

1662

Unique # Participated *

PARTICIPANTS

416

Responses Validated *

VALIDATIONS

187

* Login to view program details and full enterprise executive list.


  •  DATE

    JULY 2020

  •  TABLES

    303

  •  PAGES

    570

  •  EDITION

    19

  •  PRICE

    USD $5600


GLOBAL EXECUTIVE SURVEY

Impact of Pandemic & Economic Slowdown

Monitor Market Dynamics!
Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here.

With routine healthcare services severely disrupted amid the pandemic, the global market for traditional wound management products is projected to reach a revised size of US$6. 6 billion by the year 2027, after recovering from -2. 1% drop in demand in 2020. Access to healthcare services by chronic wound patients remains disrupted as healthcare resources are repurposed and focused for the treatment of COVID-19 patients. With infections continuing to rise worldwide, healthcare systems are overburdened by the flood of COVID-19 patients requiring hospital care. Several countries are emptying hospitals beds occupied by non-corona virus patients before the pandemic to make space for the arrival of COVID-19 patients. In Hungary, over 69.2%, 75.6%, 62.4% and 42.1% of existing hospital beds were emptied to accommodate COVID-19 patients in the month January, February, March, and April 2020 respectively. Routine healthcare services are especially worst hit in countries with less abundant healthcare such as India, Bangladesh, Pakistan, Brazil, Indonesia, Ethiopia, Tanzania, Congo and Uganda. Against the backdrop of large reallocation of healthcare personnel/facilities to COVID-19 response and management, there is a sizable shrinking of the provision of non-COVID healthcare services across the entire medical/healthcare spectrum. Wound care clinics are no exception and reduced visits to clinics; lack of access to timely care; and shift to homecare settings have reduced demand momentum for wound management products.

In the United States and other countries worldwide, physicians have been unable to see new patients as outpatient wound clinics remain closed. Shortage of appropriate PPE equipment is the single most important factor responsible for closure of clinics treating non-COVID patients. Given that traditional wound care products are used in treating low and medium severity wounds, the rescheduling of patients with low risk wounds has impacted the market significantly. Wound care hospitals are prioritizing service provision to only high risk patients such as those with necrotic tissue and those actively undergoing serial debridement; or patients being treated with CTP and compression with high drainage. Several hospitals are also utilizing dressings that will allow decreased intensity of wound care, which is resulting in a sharp decrease in the volume of clinical procedures. Homes are increasingly considered to be the safest environment with the lowest risk of COVID-19 exposure for wound patients requiring care. As telemedicine and home care storm into the spotlight, supplying wound dressings in single-dose packages will gain prominence. Single-dose packages help in avoiding confusion and prevent their improper use among patients learning to self-care for their wounds. ecommerce retailing platforms will grow in prominence and will temporarily supplant local brick and motor sources.

The post COVID-19 period will witness growth coming from much-needed innovations, given the unmet needs in self-administering wound care products. Easy to use injectable bandage is one such example of an innovation that will benefit home based wound management. Inspired Nan materials and Tissue Engineering Laboratory researchers at Texas A&M University developed an innovative injectable bandage that stops wound bleeding and promotes healing. The gelling agent kappa-carrageen an based bandage can be introduced into wounds with minimally invasive procedures. The injectable bandage solidifies after injection and promotes natural clotting. The researchers used kappa-carrageen an mixed with charged clay-based nanoparticles, to obtain an injectable gelatin with haemostatic ability. Platelets and plasma proteins form blood absorption on the hydro gel and initiate the blood clotting cascade.

>
» Product (Gauzes, Bandages, Other Products) » Application (Acute Wounds, Chronic Wounds) » End-Use (Hospitals, Clinics, Home Healthcare, Other End-Uses)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com